Method of treating attention deficit disorder

Abstract

Methods and compositions for treating humans suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or a condition where inhibiting reuptake of norepinephrine is a benefit are disclosed. The compositions comprise a compound having a pharmacological selectivity of serotonin (K i )/norepinephrine (K i ) of at least about 5000. Examples of such compounds include reboxetine, and more preferably optically pure (S,S) enantiomer of reboxetine. The methods generally include administration of a therapeutic amount of such compositions. Also disclosed are preparations of a medicament from the composition, and uses of the composition in a manufacture of the medicament to treat a human suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or condition.

1 . A method of treating an individual suffering from an attention-deficit disorder due to general medical conditions, the method comprising the step of administering to the individual a therapeutically effective amount of optically pure (S,S) reboxetine, or a pharmaceutically acceptable salt thereof. 
   
   
       2 . The method of  claim 1  wherein said optically pure (S,S) reboxetine or a pharmaceutically acceptable salt thereof, is administered in an amount of about 0.1 to about 10 mg/day. 
   
   
       3 . The method of  claim 2  wherein said optically pure (S,S) reboxetine, or a pharmaceutically acceptable salt thereof, is administered in an amount of about 0.5 to about 8 mg/day. 
   
   
       4 . The method of  claim 3  wherein said optically pure (S,S) reboxetine or a pharmaceutically acceptable salt thereof, is administered in an amount of about 0.5 to about 5 mg/day. 
   
   
       5 . The method of  claim 4  wherein said optically pure (S,S) reboxetine, or a pharmaceutically acceptable salt thereof, is administered in an amount of about 0.5 to about 2.5 mg/day. 
   
   
       6 . The method of  claim 5  wherein said optically pure (S,S) reboxetine or a pharmaceutically acceptable salt thereof, is administered in an amount of about 0.5 to about 0.9 mg/day. 
   
   
       7 . The method of  claim 6  wherein said optically pure (S,S) reboxetine or a pharmaceutically acceptable salt thereof, is administered in an amount of about 0.5 to about 0.8 mg/day. 
   
   
       8 . The method of  claim 7  wherein said optically pure (S,S) reboxetine or a pharmaceutically acceptable salt thereof, is administered in an amount of about 0.5 to about 0.75 mg/day. 
   
   
       9 . The method of  claim 1  wherein said optically pure (S,S) reboxetine or a pharmaceutically acceptable salt thereof, is administered as a composition and said composition is administered orally, topically, parenterally, transdermally, rectally, or vaginally. 
   
   
       10 . The method of  claim 9  wherein said composition is orally administered, and further comprising a pharmaceutically acceptable carrier selected from the group consisting of a binder, diluent, lubricant, disintegrating agent, effervescing agent, dyestuff, sweetener, wetting agent, and mixtures thereof. 
   
   
       11 . The method of  claim 10  wherein the oral administration is by a sachet, capsule, tablet, or aerosol spray. 
   
   
       12 . The method of  claim 9  wherein said composition is parenterally administered subcutaneously, intravenously, or intramuscularly. 
   
   
       13 . (canceled) 
   
   
       14 . The method of  claim 1  wherein the pharmaceutically acceptable salt is a methanesulfonate salt. 
   
   
       15 - 23 . (canceled) 
   
   
       24 . (canceled) 
   
   
       25 - 38 . (canceled) 
   
   
       39 - 41 . (canceled) 
   
   
       42 . (canceled) 
   
   
       43 . (canceled) 
   
   
       44 - 69 . (canceled)